The DoD’s Medical Countermeasure Systems-Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office is responsible for the development, procurement, fielding, and sustaining of such medical treatments and prophylactic capabilities against chemical, radiological and nuclear threats. The current MCS-CDP portfolio includes nerve agent therapeutics, pretreatments and prophylactics at varying stages of clinical development, including FDA-approved drugs.
Currently, MCS-CDP is seeking capabilities from interested parties for the advanced development of the centrally-acting therapeutic scopolamine for intramuscular administration by military Service Members for use as an adjunct in conjunction with the pretreatment pyridostigmine bromide (PB) as well as the oxime/atropine and anticonvulsant therapies.
This Request for Information (RFI) seeks to identify existing sources for the active pharmaceutical ingredient scopolamine hydrobromide, and identify expertise for the development and/or manufacture of the drug product/ substance for FDA approval.
Further details are available via Solicitation Number: W911QY15S0007. Responses are due by April 8, 2015.